Effects of anticoagulants on human plasma soluble corin levels measured by ELISA

Clinica Chimica Acta

Volumn 411, Issue 23-24, 2010, Pages 1998-2003

  Dong, Ningzheng ^a   Dong, Jing ^a   Liu, Peng ^a   Xu, Luyao ^a   Shi, Sengseng ^a   Wu, Qingyu ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anticoagulants; Corin; Heart failure; Membrane proteases

Indexed keywords

CITRATE SODIUM; CORIN; EDETIC ACID; HEPARIN; RECOMBINANT PROTEIN; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME STABILITY; FEMALE; FREEZE THAWING; HUMAN; HUMAN CELL; INCUBATION TIME; MALE; NORMAL HUMAN; NORMAL VALUE; PRIORITY JOURNAL; ROOM TEMPERATURE; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTIFACTS; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; REFERENCE VALUES; SERINE ENDOPEPTIDASES; SOLUBILITY; YOUNG ADULT;

EID: 77957752136     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.08.021     Document Type: Article

References (33)

1. Hooper J.D., Scarman A.L., Clarke B.E., Normyle J.F., Antalis T.M. Localization of the mosaic transmembrane serine protease corin to heart myocytes. Eur J Biochem 2000, 267:6931-6937.
2. Wu Q. The serine protease corin in cardiovascular biology and disease. Front Biosci 2007, 12:4179-4190.
3. Wu Q., Xu-Cai Y.O., Chen S., Wang W. Corin: new insights into the natriuretic peptide system. Kidney Int 2009, 75:142-146.
4. Enshell-Seijffers D., Lindon C., Morgan B.A. The serine protease corin is a novel modifier of the Agouti pathway. Development 2008, 135:217-225.
5. Ono Y., Nakatani T., Sakamoto Y., Mizuhara E., Minaki Y., Kumai M., et al. Differences in neurogenic potential in floor plate cells along an anteroposterior location: midbrain dopaminergic neurons originate from mesencephalic floor plate cells. Development 2007, 134:3213-3225.
6. Yan W., Sheng N., Seto M., Morser J., Wu Q. Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. J Biol Chem 1999, 274:14926-14935.
7. Chan J.C., Knudson O., Wu F., Morser J., Dole W.P., Wu Q. Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci USA 2005, 102:785-790.
8. Nigrovic P.A., Gray D.H., Jones T., Hallgren J., Kuo F.C., Chaletzky B., et al. Genetic inversion in mast cell-deficient (W(sh)) mice interrupts corin and manifests as hematopoietic and cardiac aberrancy. Am J Pathol 2008, 173:1693-1701.
9. Dries D.L., Victor R.G., Rame J.E., Cooper R.S., Wu X., Zhu X., et al. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation 2005, 112:2403-2410.
10. Rame J.E., Drazner M.H., Post W., Peshock R., Lima J., Cooper R.S., et al. Corin I555(P568) allele is associated with enhanced cardiac hypertrophic response to increased systemic afterload. Hypertension 2007, 49:857-864.
11. Rame J.E., Tam S.W., McNamara D., Worcel M., Sabolinski M.L., Wu A.H., et al. Dysfunctional corin I555(P568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy. Circ Heart Fail 2009, 2:541-548.
12. Wang W., Liao X., Fukuda K., Knappe S., Wu F., Dries D.L., et al. Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity. Circ Res 2008, 103:502-508.
13. Bugge T.H., Antalis T.M., Wu Q. Type II transmembrane serine proteases. J Biol Chem 2009, 284:23177-23181.
14. Wu Q. Type II transmembrane serine proteases. Curr Top Dev Biol 2003, 54:167-206.
15. Yan W., Wu F., Morser J., Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA 2000, 97:8525-8529.
16. Lin C.Y., Anders J., Johnson M., Dickson R.B. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999, 274:18237-18242.
17. Wu Q. Gene targeting in hemostasis. Hepsin. Front Biosci 2001, 6:D192-D200.
18. Peleg A., Jaffe A.S., Hasin Y. Enzyme-linked immunoabsorbent assay for detection of human serine protease corin in blood. Clin Chim Acta 2009, 409:85-89.
19. Dong N., Chen S., Yang J., He L., Liu P., Zheng D., Li L., Zhou Y., Ruan C., Plow E., Wu Q. Plasma soluble corin in patients with heart failure. Circ Heart Fail 2010, 3:207-211.
20. Shrestha K., Troughton R.W., Borowski A.G., Yandle T.G., Richards A.M., Klein A.L., Tang W.H. Plasma corin levels provide minimal prognostic utility incremental to natriuretic peptides in chronic systolic heart failure. J Card Fail 2010, 16:621-627.
21. Knappe S., Wu F., Madlansacay M.R., Wu Q. Identification of domain structures in the propeptide of corin essential for the processing of proatrial natriuretic peptide. J Biol Chem 2004, 279:34464-34471.
22. Knappe S., Wu F., Masikat M.R., Morser J., Wu Q. Functional analysis of the transmembrane domain and activation cleavage of human corin. J Biol Chem 2003, 278:52363-52370.
23. Liao X., Wang W., Chen S., Wu Q. Role of glycosylation in corin zymogen activation. J Biol Chem 2007, 282:27728-27735.
24. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med 1998, 339:321-328.
25. Ayache S., Panelli M., Marincola F.M., Stroncek D.F. Effects of storage time and exogenous protease inhibitors on plasma protein levels. Am J Clin Pathol 2006, 126:174-184.
26. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
27. Daniels L.B., Maisel A.S. Natriuretic peptides. J Am Coll Cardiol 2007, 50:2357-2368.
28. Luckenbill K.N., Christenson R.H., Jaffe A.S., Mair J., Ordonez-Llanos J., Pagani F., et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem 2008, 54:619-621.
29. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
30. Wu A.H. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 2006, 152:828-834.
31. Wu A.H., Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 2004, 6:355-358.
32. Xu-Cai Y.O., Wu Q. Molecular forms of natriuretic peptides in heart failure and their implications. Heart 2010, 96:419-424.
33. Shi X., Xu G., Xia T., Song Y., Lin Q. N-terminal-pro-B-type natriuretic peptide (NT-proBNP): reference range for Chinese apparently healthy people and clinical performance in Chinese elderly patients with heart failure. Clin Chim Acta 2005, 360:122-127.